Effects of Treatment Adherence on Quality of Life in Hypoparathyroid Patients

Basit Öğe Kaydı
dc.contributor.authorAnaforoglu, Inan
dc.contributor.authorSancak, Seda
dc.contributor.authorAkbas, Emin Murat
dc.contributor.authorOruk, Guzide Gonca
dc.contributor.authorCanat, Masum
dc.contributor.authorTezcan, Kadriye Aydln
dc.contributor.authorUc, Ziynet Alphan
dc.date.accessioned2024-10-26T17:51:44Z
dc.date.available2024-10-26T17:51:44Z
dc.date.issued2021
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractObjectives This study aimed to evaluate the current situation of hypoparathyroid patients and to investigate the relationship between treatment adherence and quality of life. Study design Prospective, multicentre study. Methods Adult patients presenting with the diagnosis of hypoparathyroidism to 20 different endocrinology clinics were included. They were receiving conventional therapies for hypoparathyroidism, using calcium, active vitamin D, and magnesium. We collected data on demographic features, disease- and treatment-related information, and results of routine laboratory tests, treatment adherence, and presence of complications. Beck Depression Inventory, Beck Anxiety Inventory, and Short Form-36 quality of life assessments were administered. Results Among the 300 patients studied, 60.7 % were adherent to their treatment, and 34.1 % had complications. Anxiety and depression scores were significantly higher in non-adherent versus treatment-adherent patients (p ? 0.001 and p = 0.001, respectively). Most of the domains of quality-of-life scores were also significantly lower in non-adherent patients. Both anxiety and depression scores showed significant, negative correlations with serum calcium and magnesium concentrations (r = -0.336, p ? 0.001 and r = -0.258, p ? 0.001, respectively). Conclusions Nearly 40 % of the patients were non-adherent to conventional treatment for hypoparathyroidism, and such patients had higher anxiety and depression scores and poorer quality of life scores. Conventional treatment might not be sufficient to meet the needs of patients with hypoparathyroidism. In addition to seeking new therapeutic options, factors influencing quality of life should also be investigated and strategies to improve treatment adherence should be developed. © 2021 Georg Thieme Verlag. All rights reserved.
dc.identifier.doi10.1055/a-1400-2668
dc.identifier.endpage925
dc.identifier.issn0947-7349
dc.identifier.issue12
dc.identifier.pmid33694151
dc.identifier.scopus2-s2.0-85102589360
dc.identifier.scopusqualityQ2
dc.identifier.startpage918
dc.identifier.urihttps://doi.org/10.1055/a-1400-2668
dc.identifier.urihttps://hdl.handle.net/20.500.12418/26386
dc.identifier.volume129
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherGeorg Thieme Verlag
dc.relation.ispartofExperimental and Clinical Endocrinology and Diabetes
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectconventional treatment; hypoparathyroidism; quality of life; treatment adherence
dc.titleEffects of Treatment Adherence on Quality of Life in Hypoparathyroid Patients
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu